Aileron Therapeutics' Phase 1b trial shows LTI-03 improved biomarkers and reduced SPD levels, indicating the potential to ...

Sino-American firm Insilico Medicine has shown the potential not just of its pipeline and lead candidate by presenting ...

特发性肺纤维化（idiopathic pulmonary fibrosis, IPF ）是一种不明原因的慢性纤维化间质性肺炎，其特征是呼吸困难和肺功能进行性恶化[1] 。IPF 影响着全球约300 万人，且老年人的发病率不断升高[2] 。IPF ...

In a small Phase IIa trial, Insilico’s generative AI-designed idiopathic pulmonary fibrosis drug improved lung function and ...

The topline data showed ISM001-055 to have improved the forced vital capacity (FVC) of IPF patients studied 12 weeks after ...

马萨诸塞州沃尔瑟姆 - 生物制药公司Aileron Therapeutics, Inc. (NASDAQ: ALRN)宣布了其针对特发性肺纤维化(IPF)的新型治疗候选药物LTI-03的1b期临床试验第二组队列的积极结果。该试验评估了吸入型LTI-03（一种与Caveolin-1相关的肽）在IPF患者中的安全性和药效学特性。 试验显示,在给予高剂量LTI-03(5 mg BID)后,8个IPF生物 ...

自从2011年IPF诊疗指南发布，经过大量的临床试验吡非尼酮和尼达尼布被美国FDA批准上市，应用于IPF的治疗中。这2种药物对于轻到中度肺功能损害的IPF患者能起到改善肺功能的下降、延缓疾病进程的目的，同时也提出早期诊断和早期治疗的重要性。

The development of a novel, artificial intelligence (AI)-generated biotechnology has the potential to transform care options ...

Overall, the collective findings from this Phase 1b clinical trial provide the Company with strong confidence that LTI-03 has ...

周一，H.C. Wainwright重申了对Pliant Therapeutics (NASDAQ:PLRX)股票的买入评级，目标价维持在$38.00。该公司的乐观态度源于bexotegrast治疗特发性肺纤维化(IPF)的BEACON-IPF临床试验的进展。该试验正按计划进行，预计患者招募将在2025年第一季度结束。 BEACON-IPF试验是一项为期52周的研究，旨在评估bexotegrast ...

Columnist Sam Kirton encourages the IPF community to get a jump on legislative advocacy before the new congressional term begins.

“A highlight to this quarter’s progress was the continued strong execution of our BEACON-IPF Phase 2b/3 trial which is ...